Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Sezary syndrome
Stage/Subtype:  stage I mycosis fungoides/Sezary syndrome
Country:  U.S.A.
Trial Type:  Treatment
Results 1-25 of 29 for your search:
Start Over
Autologous Peripheral Blood Stem Cell Transplant in Treating Patients with Lymphoma
Status: Active
Phase: Phase III, Phase II
Type: Treatment
Age: Under 70
Trial IDs: MT 2004-24, NCI-2010-01414, 0508M72589, 2005LS048, UMN-2005LS048, UMN-0508M72589, UMN-MT2004-24, NCT00345865
A Trial of E7777 in Persistent and Recurrent Cutaneous T-Cell Lymphoma
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: E7777-G000-302, NCI-2013-00713, NCT01871727
Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: Not specified
Trial IDs: 95-024, NCI-2017-00824, MSKCC-95024, NCI-V95-0685, P30CA008748, NCT00002663
Autologous or Donor Cytotoxic T-Lymphocytes in Treating Patients with Epstein-Barr Virus-Positive Hematologic Malignancy
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: Any age
Trial IDs: ALCI, NCI-2012-00653, 9936-ALCI, H-9936, NCT00070226, NCT00671164, NCT00062868
Low-Dose Donor Bone Marrow Transplant in Treating Patients with Hematologic Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 6 montha to 70
Trial IDs: J1055, NCI-2011-00377, NCT01203722
Dasatinib in Treating Patients with Multiple Myeloma, Non-Hodgkin, or Hodgkin Lymphoma Previously Treated with Autologous Stem Cell Transplant
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CA-180-381, NCI-2012-00767, 1203010693, 2011-203, NCT01609816
Azacitidine in Treating Patients Undergoing Matched Unrelated Stem Cell Transplant
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 65
Trial IDs: 201303012, NCI-2012-03105, NCT01747499
CD34+ Stem Cell Selection in Preventing Graft-Versus-Host Disease in Younger Patients with Malignant Disease Undergoing Donor Stem Cell Transplant
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: Under 22
Trial IDs: AAAK8060, NCI-2014-00137, NCT02061800
A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Oral eFT508 in Subjects With Hematological Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: eFT508-0002, NCI-2017-00209, NCT02937675
Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients with Hematologic Malignancies Undergoing Donor Peripheral Blood Stem Cell Transplant
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Age: Not specified
Trial IDs: 2206.00, NCI-2010-02222, NCT01251575
Two Step Donor Stem Cell Transplant in Treating Patients with High-Risk Hematological Malignancies
Status: Active
Phase: Phase II
Type: Supportive care, Treatment
Age: 18 and over
Trial IDs: 08D.85, NCI-2012-00407, 2007-61, NCT01315132
Safety Study of Cord Blood Units for Stem Cell Transplants
Status: Active
Phase: Phase II
Type: Treatment
Age: Any age
Trial IDs: 130116, NCI-2014-01832, 13-H-0116, NCT01861093
Chemotherapy, Stem Cell Transplant, and Romidepsin in Treating Patients with T-cell Non-Hodgkin Lymphoma
Status: Active
Phase: Phase II
Type: Treatment
Age: Over 16
Trial IDs: 13-020, NCI-2013-01365, NCT01908777
Romidepsin and Lenalidomide in Treating Patients with Previously Untreated Peripheral T-Cell Lymphoma
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: NU 14H04, NCI-2014-01770, RV-CL-PTCL-PI-003974, STU00097620, NCT02232516
NM-IL-12 in Cutaneous T-Cell Lymphoma (CTCL) Undergoing Total Skin Electron Beam Therapy (TSEBT)
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: NM-ONC-001, NCI-2016-00046, NCT02542124
A Long-term, Continued Treatment and Follow-up Study in Subjects With Hematologic Malignancies Treated With Duvelisib (IPI-145)
Status: Enrolling by invitation
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: IPI-145-23, NCI-2016-01196, NCT02711852
A Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: INCB 54828-203, NCI-2017-00141, NCT03011372
Pembrolizumab and Interferon Gamma-1b in Treating Patients with Stage IB-IVB Relapsed or Refractory Mycosis Fungoides and Sezary Syndrome
Status: Not yet active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: CITN-13, NCI-2017-00265, NCT03063632
Epstein-Barr Virus-Specific Cytotoxic T Lymphocytes in Treating Patients With Newly Diagnosed or Recurrent Hodgkin Lymphoma or Non-Hodgkin Lymphoma
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: Not specified
Trial IDs: CAR CD30, NCI-2012-00640, H-26617, NCT01192464
Donor Cytotoxic T-Lymphocytes in Treating Patients With Relapsed Epstein-Barr Virus-Associated Diseases
Status: Active
Phase: Phase I
Type: Treatment
Age: Any age
Trial IDs: MALTED, NCI-2012-01079, H-28361, NCT01447056
Modified T-Cells in Treating Patients With Epstein-Barr Virus Positive Lymphoma.
Status: Active
Phase: Phase I
Type: Treatment
Age: Not specified
Trial IDs: H-29617, NCI-2013-01016, GRALE, NCT01555892
HIV-Resistant Gene Modified Stem Cells and Chemotherapy in Treating Patients with Lymphoma with HIV Infection
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 66
Trial IDs: 2673.00, NCI-2014-02395, 2673, NCT02343666
Safety, Tolerability and Pharmacokinetic Study of MRG-106 in Patients With Cutaneous T Cell Lymphoma (CTCL), MF Subtype
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 80
Trial IDs: MRG106-11-101, NCI-2015-01960, NCT02580552
Start Over